Enorama Pharma Past Earnings Performance
Past criteria checks 0/6
Enorama Pharma's earnings have been declining at an average annual rate of -14.6%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 10.4% per year.
Key information
-14.6%
Earnings growth rate
14.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | -10.4% |
| Return on equity | -105.4% |
| Net Margin | -268.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Enorama Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 13 | -36 | 32 | 0 |
| 30 Jun 24 | 6 | -41 | 34 | 0 |
| 31 Mar 24 | 1 | -42 | 34 | 0 |
| 31 Dec 23 | 1 | -45 | 34 | 0 |
| 30 Sep 23 | 1 | -44 | 36 | 0 |
| 30 Jun 23 | 5 | -39 | 33 | 0 |
| 31 Mar 23 | 7 | -41 | 36 | 0 |
| 31 Dec 22 | 7 | -42 | 38 | 0 |
| 30 Sep 22 | 11 | -37 | 34 | 0 |
| 30 Jun 22 | 9 | -38 | 37 | 0 |
| 31 Mar 22 | 10 | -33 | 33 | 0 |
| 31 Dec 21 | 13 | -28 | 30 | 0 |
| 30 Sep 21 | 10 | -28 | 33 | 0 |
| 30 Jun 21 | 8 | -25 | 28 | 0 |
| 31 Mar 21 | 6 | -24 | 25 | 0 |
| 31 Dec 20 | 4 | -23 | 25 | 0 |
| 30 Sep 20 | 5 | -22 | 22 | 0 |
| 30 Jun 20 | 7 | -25 | 24 | 0 |
| 31 Mar 20 | 10 | -25 | 25 | 0 |
| 31 Dec 19 | 10 | -24 | 24 | 0 |
| 30 Sep 19 | 11 | -23 | 11 | 0 |
| 30 Jun 19 | 11 | -19 | 8 | 0 |
| 31 Mar 19 | 9 | -18 | 7 | 0 |
| 31 Dec 18 | 12 | -16 | 6 | 0 |
| 30 Sep 18 | 11 | -13 | 10 | 0 |
| 30 Jun 18 | 10 | -11 | 8 | 0 |
| 31 Mar 18 | 10 | -10 | 6 | 0 |
| 31 Dec 17 | 5 | -9 | 3 | 0 |
| 30 Sep 17 | 3 | -8 | 1 | 0 |
| 30 Jun 17 | 5 | -6 | 0 | 0 |
| 31 Mar 17 | 3 | -8 | 2 | 0 |
| 31 Dec 16 | 4 | -8 | 2 | 0 |
| 30 Sep 16 | 6 | -5 | 8 | 0 |
| 30 Jun 16 | 4 | -4 | 7 | 0 |
| 31 Mar 16 | 3 | -1 | 4 | 0 |
| 31 Dec 15 | 2 | -1 | 3 | 0 |
| 31 Dec 14 | 1 | 0 | 1 | 0 |
Quality Earnings: ERMA is currently unprofitable.
Growing Profit Margin: ERMA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ERMA is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.
Accelerating Growth: Unable to compare ERMA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ERMA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.2%).
Return on Equity
High ROE: ERMA has a negative Return on Equity (-105.43%), as it is currently unprofitable.